Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Daniel Vaena

Hematology | Oncology
The West Clinic, PLLC
7668 Airways Blvd, 
Southaven, MS 
Offers Telehealth
Distinguished in WT1-Related Wilms Tumor Syndromes
The West Clinic, PLLC
7668 Airways Blvd, 
Southaven, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Vaena is a Hematologist and an Oncologist in Southaven, Mississippi. Dr. Vaena is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, WT1-Related Wilms Tumor Syndromes, and Clear Cell Sarcoma.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Methodist Hospitals Of Memphis
Baptist Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

THE WEST CLINIC, PLLC
7668 Airways Blvd, Southaven, MS 38671
Other Locations
THE WEST CLINIC, PLLC
7945 Wolf River Blvd, Germantown, TN 38138

Additional Areas of Focus

Dr. Vaena has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: TTX-030, Pembrolizumab, Docetaxel, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Study Phase: Phase 3
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
Enrollment Status: Terminated
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Head and Neck Cancer
A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: June 26, 2018
Intervention Type: Dietary supplement, Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

24 Total Publications

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Journal: JAMA network open
Published: October 07, 2024
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David Portnoy
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David Portnoy
Hematology | Oncology

The West Clinic, PLLC

7945 Wolf River Blvd, 
Germantown, TN 
 (14.4 miles away)
901-683-0055
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Portnoy is a Hematologist and an Oncologist in Germantown, Tennessee. Dr. Portnoy is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma Embryonal, Retroperitoneal Liposarcoma, and Pancreaticoduodenectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kurt Tauer
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kurt Tauer
Hematology | Oncology

The West Clinic, PLLC

1588 Union Ave, 
Memphis, TN 
 (11.3 miles away)
901-300-1562
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kurt Tauer is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Tauer is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Familial Colorectal Cancer.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sylvia Richey
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sylvia Richey
Hematology | Oncology

The West Clinic, PLLC

6055 Primacy Pkwy, Suite 100, 
Memphis, TN 
 (11.0 miles away)
901-440-4129
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sylvia Richey is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Richey is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Orchiectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vaena's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 34 Advanced Conditions
    View All 145 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile